Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

被引：0

作者：

Gee-Chen Chang

David Chi-Leung Lam

Chun-Ming Tsai

Yuh-Min Chen

Jin-Yuan Shih

Shyam Aggarwal

Shuhang Wang

Sang-We Kim

Young-Chul Kim

Ibrahim Wahid

Rubi Li

Darren Wan-Teck Lim

Virote Sriuranpong

Raymond Tsz-Tong Chan

Robert M. Lorence

Philippe Carriere

Christina Raabe

Agnieszka Cseh

Keunchil Park

机构：

[1] Taichung Veterans General Hospital,Division of Chest Medicine, Department of Internal Medicine

[2] Chung Shan Medical University Hospital,Division of Pulmonary Medicine, Department of Internal Medicine

[3] Chung Shan Medical University,Institute of Medicine and School of Medicine

[4] Queen Mary Hospital,Department of Chest Medicine

[5] The University of Hong Kong,Asan Medical Center

[6] Taipei Veterans General Hospital,Samsung Medical Center

[7] Taipei Veterans General Hospital,undefined

[8] and School of Medicine,undefined

[9] National Yang-Ming Medical University,undefined

[10] National Taiwan University Hospital,undefined

[11] Sir Ganga Ram Hospital Rajinder Nagar,undefined

[12] Beijing Cancer Hospital,undefined

[13] University of Ulsan College of Medicine,undefined

[14] Chonnam National University,undefined

[15] Hwasun Hospital,undefined

[16] Beacon International Specialist Centre,undefined

[17] St Luke’s Medical Center,undefined

[18] National Cancer Centre,undefined

[19] Chulalongkorn University and the King Chulalongkorn Memorial Hospital,undefined

[20] Hong Kong Pacific Centre,undefined

[21] Boehringer Ingelheim Pharmaceuticals,undefined

[22] Inc.,undefined

[23] Boehringer Ingelheim International GmbH,undefined

[24] Boehringer Ingelheim RCV GmBH & Co. KG,undefined

[25] Sungkyunkwan University School of Medicine,undefined

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Afatinib; mutations; Lung cancer; Named patient use; NSCLC; Uncommon ; mutations;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：841 / 850

页数：9

共 50 条

[31] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [J].

Paz-Ares, L. ;

Tan, E. -H. ;

O'Byrne, K. ;

Zhang, L. ;

Hirsh, V. ;

Boyer, M. ;

Yang, J. C. -H. ;

Mok, T. ;

Lee, K. H. ;

Lu, S. ;

Shi, Y. ;

Lee, D. H. ;

Laskin, J. ;

Kim, D. -W. ;

Laurie, S. A. ;

Kolbeck, K. ;

Fan, J. ;

Dodd, N. ;

Marten, A. ;

Park, K. .

ANNALS OF ONCOLOGY, 2017, 28 (02) :270-277

[32] Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy [J].

Minchom, Anna ;

Viteri, Santiago ;

Bazhenova, Lyudmila ;

Gadgeel, Shirish M. ;

Ou, Sai-Hong Ignatius ;

Trigo, Jose ;

Bauml, Joshua M. ;

Backenroth, Daniel ;

Bhattacharya, Archan ;

Li, Tracy ;

Mahadevia, Parthiv ;

Girard, Nicolas .

LUNG CANCER, 2022, 168 :74-82

[33] EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China [J].

Xu, Jianlin ;

Jin, Bo ;

Chu, Tianqing ;

Dong, Xue ;

Yang, Haitang ;

Zhang, Yanwei ;

Wu, Dan ;

Lou, Yuqing ;

Zhang, Xueyan ;

Wang, Huiming ;

Han, Baohui .

LUNG CANCER, 2016, 96 :87-92

[34] Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer [J].

Liam, C. ;

Ho, G. ;

Chai, C. ;

Alip, A. Bt ;

Pang, Y. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S998-S999

[35] The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations-The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations [J].

Tan, Jiarong ;

Hu, Chengping ;

Deng, Pengbo ;

Wan, Rongjun ;

Cao, Liming ;

Li, Min ;

Yang, Huaping ;

Gu, Qihua ;

An, Jian ;

Jiang, Juan .

FRONTIERS IN ONCOLOGY, 2021, 11

[36] Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations [J].

Chen, Dan ;

Song, Zhengbo ;

Cheng, Guoping .

ONCOTARGETS AND THERAPY, 2016, 9 :4181-4186

[37] Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials [J].

Passaro, Antonio ;

Gori, Bruno ;

de Marinis, Filippo .

JOURNAL OF THORACIC DISEASE, 2013, 5 (04) :383-384

[38] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer [J].

Liam, C. K. ;

Chai, C. ;

Ho, G. ;

Alip, A. ;

Wahid, M. I. A. ;

Abdullah, M. M. ;

Foo, Y. C. ;

How, S. H. ;

Zaatar, A. ;

Lam, K. S. ;

Leong, K. W. ;

Low, J. S. H. ;

Yusof, M. Md .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S848-S848

[39] Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations [J].

Yamada, Yutaka ;

Imai, Hisao ;

Sugiyama, Tomohide ;

Minemura, Hiroyuki ;

Kanazawa, Kenya ;

Kasai, Takashi ;

Minato, Koichi ;

Kaira, Kyoichi ;

Kaburagi, Takayuki .

MEDICINA-LITHUANIA, 2021, 57 (09)

[40] Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer [J].

Leighl, Natasha B. ;

Karaseva, Nina ;

Nakagawa, Kazuhiko ;

Cho, Byoung-Chul ;

Gray, Jhanelle E. ;

Hovey, Tina ;

Walding, Andrew ;

Ryden, Anna ;

Novello, Silvia .

EUROPEAN JOURNAL OF CANCER, 2020, 125 :49-57

← 1 2 3 4 5 →